Updated on 6 January 2014
Natco to continue selling Nexavar generic
The Intellectual Property Appellate Board (IPAB) upheld a decision to allow Natco Pharma to sell a generic version of Bayer AG's cancer drug Nexavar.
Novartis investigates its drug's promotion
Novartis discovered that 18 of its employees are promoting its diabetes drug Galvus using unethical means to wholesalers in India and has launched an investigation.
MNCs up China presence
Moving beyond the promises of cheap labor and production costs, China has emerged as a favorable place for drug discovery and manufacturing with multinationals stepping up investments for capacity building.
Sanofi pays $109 mn to settle Hyalgan case
Sanofi US will pay $109 million as part of a settlement with the US Attorney's Office, District of Massachusetts. Sanofi had voluntarily stopped sampling of visco supplement Hyalgan in 2009 after it identified concerns in the product through its compliance program.
India launched its first eHealth Center in Haryana
CSIR and HP have launched a health cloud-enabled eHealth Center in Haryana, India, to help improve healthcare access in rural areas.